Cancer Chemo- and Immunopharmacology: 1. Chemopharmacology

Front Matter....Pages I-XIII
General Progress in Clinical Chemotherapy of Advanced Disease....Pages 1-7
Adjuvant Therapies of Postsurgical Minimal Residual Disease....Pages 8-25
Limits of Animal Models in Cancer Chemotherapy....Pages 26-30
Clinical Chemotherapy: Its Correlation with Experimental Models....Pages 31-36
Metabolic Conversion of Methotrexate in Man....Pages 37-41
Biochemical Control of High-Dose Methotrexate/Leucovorin Rescue Therapy....Pages 42-49
High-Dose Methotrexate in Combination Chemotherapy for Small Cell Lung Cancer....Pages 50-55
Clinical and Laboratory Reevalution of Dichloromethotrexate....Pages 56-64
An Overview of the Clinical Pharmacology of N-Phosphonacetyl- L -Aspartate (PALA), a New Antimetabolite....Pages 65-71
N-(Phosphonacetyl)- L -Aspartate (PALA): Current Status....Pages 72-77
Synthesis, Biologic Effects, and Biochemical Properties of Some 2’-Azido- and 2’-Amino-2’-Deoxyarabinofuranosyl Pyrimidines and Purines....Pages 78-83
Prediction of Clinical Response to 5-Fluorouracil-Containing Chemotherapy: Preliminary Results of in Vitro Assay in Human Breast Cancer....Pages 84-90
Vindesine: A New Vinca Alkaloid....Pages 91-97
The Epipodophyllotoxin Derivatives VM-26 and VP-16-213, 1976–1979, a Review....Pages 98-106
Antitumor Activity, Pharmacology, and Toxicity of Ellipticines, Ellipticinium, and 9-Hydroxy Derivatives: Preliminary Clinical Trials of 2-Methyl-9-Hydroxy Ellipticinium (NSC 264-137)....Pages 107-123
Comparative Pharmacokinetics of Chlorambucil and Melphalan in Man....Pages 124-131
Clinical Implications of Cisplatin Pharmacology....Pages 132-138
Cisplatinumdiamminodichloride (CPDD) in Chemotherapy of Cancers: A Phase II Therapeutic Trial....Pages 139-145
1,2-Diaminocyclohexane Platinum Derivatives of Potential Clinical Value....Pages 146-155
Preclinical and Phase I Studies of Malonatoplatinum....Pages 156-162
A Review of Clinical Studies of Pepleomycin....Pages 163-171
Experimental and Clinical Activity of a New Anthracycline Derivative: Detorubicin (14-Diethoxyacetoxydaunorubicin)....Pages 172-183
Clinical Study of Detorubicin....Pages 184-191
Preliminary Clinical Experience with 4’-Epidoxorubicin in Advanced Human Neoplasia....Pages 192-199
Quelamycin: A Summary of Phase I Clinical Trials....Pages 200-206
Current Status of Japanese Studies with the New Anthracycline Antibiotic Aclacinomycin A....Pages 207-216
Phase II Trial of Aclacinomycin in Acute Leukemia and Lymphosarcoma....Pages 217-222
Ultrastructural Study of the Cardiotoxicity and Light-Microscopic Findings of the Skin After Treatment of Golden Hamsters with Seven Different Anthracyclines....Pages 223-249
m-AMSA: A New Anticancer Agent....Pages 250-257
The Rediscovery of DON (6-Diazo-5-oxo- L -norleucine)....Pages 258-263
The Use of Peritoneal Dialysis for Delivery of Chemotherapy to Intraperitoneal Malignancies....Pages 264-269
The Development of Mesna for the Inhibition of Urotoxic Side Effects of Cyclophosphamide, Ifosfamide, and Other Oxazaphosphorine Cytostatics....Pages 270-278
Cell Kinetic Factors, Single Drugs and Combination....Pages 279-284
Hyperthermia and Chemotherapy: Preclinical Considerations....Pages 285-292
The Disposition of Intraperitoneal Bleomycin, Melphalan, and Vinblastine in Cancer Patients....Pages 293-299
Clinical Correlations of Drug Sensitivity in the Human Tumor Stem Cell Assay....Pages 300-305
Comments on the Carcinogenic, Mutagenic, and Teratogenic Properties of Anticancer Drugs....Pages 306-311
Long-Term Sequelae of Cancer Chemotherapy....Pages 312-315
Back Matter....Pages 317-318